SCHEMBL4934023

SCHEMBL4934023

NC1N=CC=CC1(N)Cc1cc(-c2ccc3cc[nH]c3c2)ccc1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 3/20 0.52
▸ APP P05067 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ ENPP2 Q13822 1/20 0.34
▸ ADORA2A P29274 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ ALOX5AP P20292 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ TNK2 Q07912 1/20 0.32
▸ DHODH Q02127 1/20 0.32
▸ CHRNB4 P30926 1/20 0.32
▸ CHRNA3 P32297 1/20 0.32
▸ CHRNA7 P36544 1/20 0.32
▸ CHRNA10 Q9GZZ6 1/20 0.32
▸ CHRNA9 Q9UGM1 1/20 0.32
▸ S1PR1 P21453 1/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4938958 0.92 BACE1 (0.46) BACE1CHRNB4CHRNA3CHRNA7CHRNA10
SCHEMBL4930995 0.91 BACE1 (0.47) BACE1CHRNB4CHRNA3CHRNA7SLC6A4
SCHEMBL4941269 0.89 BACE1 (0.55) BACE1APPMAPTCYP2D6SLC6A2
SCHEMBL4941246 0.84 NR4A2 (0.36) BACE1ADORA2AADORA1CHRNB4CHRNA3
SCHEMBL4934637 0.83 LTA4H (0.43) BACE1ADORA2AADORA1CHRNA7CYP2D6
SCHEMBL4941227 0.83 BACE1 (0.44) BACE1ADORA2AADORA1CHRNB4CHRNA3
SCHEMBL4934778 0.81 CYP11B1 (0.46) CYP2D6
SCHEMBL4939691 0.80 ABCB1 (0.43) MAPTCYP2D6CHEK1
SCHEMBL4938660 0.79 CCR5 (0.45) SLC6A4
SCHEMBL4932288 0.78 MRGPRX4 (0.38) ALOX5APSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof ASTRAZENECA AB (SE) 2008-11-20 — — US claimed
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof ASTRAZENECA AB (SE) 2008-11-20 — — US disclosed
EP-1831170-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF AstraZeneca AB (SE) 2007-09-12 — — EP disclosed
WO-2006065204-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF ASTRAZENECA AB (SE) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof PSEN2, SLC1A2, PSEN1 BACE1 30/4885APP 5/4885MAPT 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback